HISHOH Biopharma Co., Ltd. is pleased to announce that Shoji Hayashida has been appointed as a Director, effective September 2025. Mr. Hayashida possesses extensive experience in both research and development and business strategy within the pharmaceutical and biotechnology sectors, demonstrating particular leadership in the field of global medical innovation. We are confident that his appointment will further accelerate the development and business advancement of innovative immunotherapies, advancing our vision of a "World Without Allergies." Mr. Hayashida brings strengths in open innovation and industry-academia collaboration that transcend conventional boundaries, and will lead HISHOH Biopharma's future growth. We sincerely appreciate your continued support and patronage of HISHOH Biopharma.
Notice of Appointment of New Directors at HISHOH Biopharma
- HISHOH Biopharma was introduced on the LINK-J website.
- Notice Regarding Executive Personnel Changes and Transition to a Company with a Board of Directors
Author of this article
Related Articles
-
Notice regarding selection for the Drug Discovery Venture Ecosystem Enhancement Project (Drug Discovery Venture Public Offering) -
Notice Regarding Executive Personnel Changes and Transition to a Company with a Board of Directors
-
Execution of a license agreement for a substance with immunostimulatory properties and implementation of a third-party allocation of new shares in the seed round
Comments